GeoVax Labs, Inc. has entered into an unsecured $1 million revolving loan agreement with Bowery Consulting Group Inc., a financing arrangement that not only bolsters the company's balance sheet but also hands the lender substantial governance influence. The Revolving Loan Agreement, dated October 23, 2026, provides for advances of up to $1 million, subject to the lender's approval, carries a 12% annual interest rate, and matures in 12 months. The announcement, first reported by NEWMEDIAWIRE, comes as GeoVax prepares to advance its lead vaccine candidate into a pivotal Phase 3 trial.
The most consequential aspect of the deal is the sweeping board restructuring that accompanied it. On the same day the loan agreement was signed, five directors—Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan, and John Spencer, Jr.—resigned. In their place, Steven Brown, Tyler O'Brien, and Manpreet Uppal were appointed, each nominated by the lender pursuant to the agreement. The new directors will serve until the earlier of the loan's full repayment or their resignation under the agreement's terms. Following the changes, GeoVax's board consists of five directors, and the company has determined that the new appointees meet SEC and Nasdaq independence standards. O'Brien and Uppal will join the Audit Committee alongside Dr. Robert McNally.
This governance shake-up matters because it effectively gives Bowery Consulting Group a direct role in overseeing GeoVax's strategic decisions at a critical juncture. The company's priority program, GEO-MVA, is an MVA-based vaccine targeting mpox and smallpox that is advancing under an expedited regulatory pathway, with a pivotal Phase 3 trial planned for late 2026. Securing working capital was essential to keeping that timeline on track, and the financing reinforces GeoVax's balance sheet as it pursues commercialization.
CEO David A. Dodd framed the deal as a milestone. "Securing this financing is an important achievement for GeoVax, reinforcing our balance sheet and providing the working capital needed to support our operations," he said, while welcoming the new directors and thanking the departing members for their contributions. He added that the company believes it is entering "an exciting new chapter of growth and opportunity."
Still, the terms warrant scrutiny. Because advances under the facility are subject to the lender's approval, GeoVax does not have guaranteed access to the full $1 million. The 12% interest rate is relatively high, and the board turnover—while presented as a collaborative step—concentrates influence with a single creditor. Investors will be watching for the Form 8-K filing with the Securities and Exchange Commission, which will contain further details on the agreement and the new directors. More information about the company is available at www.geovax.com.
The announcement highlights the tight financing environment facing clinical-stage biotechs, where lenders can extract governance concessions in exchange for capital. For GeoVax, the infusion buys time to push GEO-MVA toward late-stage development, but it also ties the company's board composition to the loan's repayment. How the reconstituted board steers the company through the upcoming Phase 3 trial and potential commercialization will be a key story to follow.
